New Study Evaluated MASH Therapy Cost-Effectiveness
Researchers compared the long-term value of three leading treatments for metabolic dysfunction-associated steatohepatitis.
Updated on Sept. 29, 2026 in Diabetes
Live Poll
Should federal policies prioritize lower drug prices to ensure wider patient access to new therapies?
A recent study found that tirzepatide and semaglutide met standard cost-effectiveness thresholds for treating MASH in the United States, while resmetirom did not. The analysis used a lifetime Markov model to assess the clinical and financial impact of these therapies for adults with biopsy-confirmed MASH.
Why it matters
The findings aim to provide essential data for payers when determining coverage and access for high-risk patients. Given the high costs associated with treating the disease, identifying treatments that offer value is critical for sustainable healthcare spending.
The study utilized an incremental cost-effectiveness ratio of $273,445 per quality-adjusted life-year (QALY) for resmetirom, which requires a 61% price reduction to meet the benchmark. Tirzepatide and semaglutide costs were assessed against a $100,000 threshold.
The players
Diabetes, Obesity and Metabolism
This is a peer-reviewed medical journal that publishes original research articles on the treatment and management of metabolic diseases.
The details
The analysis relied on a Bayesian network meta-analysis to evaluate drug efficacy compared to a placebo, utilizing annual drug costs of $59,269 for resmetirom, $16,188 for semaglutide, and $13,036 for tirzepatide. Researchers warned that broader treatment of eligible U.S. adults could lead to annual spending exceeding $10 billion.
Timeline
Resmetirom became the first FDA-approved MASH therapy in 2024.
Semaglutide received FDA approval for MASH treatment in August 2025.
The study was published in Diabetes, Obesity and Metabolism in September 2026.
The Big Picture
The study uses the $100,000 per quality-adjusted life-year cost-effectiveness threshold to anchor its economic analysis. By applying this standard, the research clarifies which pharmaceutical interventions for MASH provide high value relative to their significant annual acquisition costs.
This analysis provides insight into how insurance providers may prioritize coverage for different MASH treatments. Patients should consult their healthcare providers to discuss which FDA-approved options are currently covered by their specific insurance plans.
The takeaway
Understanding the cost-benefit profiles of these medications is essential as payers balance rising drug expenditures with patient needs. Patients should remain informed about evolving coverage policies as more treatments enter the MASH market.
Further reading
For more information on the management of metabolic conditions, see the Diabetes section.
Source note: This article includes information reported by Ajmc.
Live Poll
Should federal policies prioritize lower drug prices to ensure wider patient access to new therapies?
